Compounded GLP-1s in 2026: what's legal, what's contested, what to check

Half the confusion in GLP-1 shopping comes from a legal regime that changed underneath the market. From 2022 through early 2025, compounded semaglutide and tirzepatide were broadly permitted because the brand drugs were in official shortage. That era is over, and what replaced it is messier: a narrower lawful lane, an aggressive litigation campaign, and a lot of marketing that hopes you won't know the difference. Here's the timeline and the current map.

Why compounding was ever allowed

U.S. law lets two kinds of pharmacies prepare medications outside normal FDA approval. State-licensed 503A compounding pharmacies make patient-specific prescriptions; FDA-registered 503B outsourcing facilities produce larger batches under federal manufacturing standards. Ordinarily, neither may compound what is "essentially a copy" of a commercially available FDA-approved drug. But when the FDA places a drug on its official shortage list, that restriction relaxes — which is how, during the 2022–2024 shortages of Wegovy, Ozempic, Mounjaro, and Zepbound, a legal mass market in compounded semaglutide and tirzepatide came to exist, often at a fifth of the brand list price.

The turn: shortages end, the clock starts

The FDA removed tirzepatide from the shortage list in late 2024 — first in October, then, after a compounders' trade group sued and the agency re-evaluated, confirming the resolution on December 19, 2024. Grace periods followed: 503A pharmacies were told to stop compounding tirzepatide copies by February 18, 2025, and 503B facilities by March 19, 2025. Semaglutide followed the same script: shortage declared resolved February 21, 2025, with 503A and 503B cutoffs of April 22 and May 22, 2025, respectively. A federal court declined to block the FDA's determinations. From mid-2025 onward, compounding copies of these drugs stopped being lawful in the way the boom years had allowed.

The contested lane: "personalized" compounding

What survived is the traditional exception: a compounded drug is not an "essential copy" if a prescriber determines a clinically meaningful difference for a specific patient — a different dose than any commercially available strength, a removed allergen, a different dosage form. Much of the post-2025 compounded GLP-1 market repositioned onto exactly this ground: "personalized dosing," intermediate titration steps, added vitamins (like B12), sublingual formats. Whether any given version of that is lawful is precisely what's being fought over. Through 2025, Eli Lilly and Novo Nordisk filed waves of lawsuits against telehealth companies and compounding pharmacies, arguing that mass-marketed "personalized" doses are copies with a costume on, along with claims about unapproved salt forms and marketing practices; several suits named prominent telehealth brands. State boards of pharmacy opened their own actions. As of early 2026, courts had not delivered a single nationwide answer — which means the practical status of a compounded GLP-1 in 2026 depends on the specific pharmacy, formulation, prescribing rationale, and state.

Meanwhile, the reason to bother shrank

The strongest argument for compounded GLP-1s was always price against a $1,000+ list. That gap narrowed hard. Lilly's direct-to-consumer Zepbound vials and Novo's cash-pay Wegovy programs put brand medication in the roughly $250–$500/month band across 2025–2026 (prices moved several times — verify current figures), and late-2025 agreements between both manufacturers and the federal government pointed cash prices for starting doses lower still into 2026. Compounded and program-based telehealth pricing in the $119–$399 range (see our ledger) can still undercut brand, especially at maintenance doses — but the era when compounding was the only affordable door is over, and any honest comparison now includes the manufacturer-direct row.

Safety is the part that doesn't depend on the lawsuits

Separate from legality: compounded drugs are not FDA-approved, and the agency reported receiving hundreds of adverse-event reports associated with compounded semaglutide and tirzepatide during the boom, many involving dosing errors — unsurprising when patients draw doses from multi-use vials in units and milliliters rather than clicking a pre-set pen. The FDA also warned specifically about products made from semaglutide salt forms (sodium, acetate) that are not the same active ingredient as the approved drug, and about counterfeit and research-grade "gray market" peptides sold without prescriptions at all — a category we treat as categorically unsafe. None of this means every compounded product is dangerous; sterile compounding under a licensed 503A/503B with the correct base ingredient is a real discipline. It means the quality floor varies in a way it doesn't for brand product, and verification is your job.

The 2026 buyer's checklist

Before paying any provider for compounded tirzepatide or semaglutide, get answers in writing to six questions. Which licensed pharmacy fills the prescription, and is it 503A or 503B? What exact active ingredient (base, not salt form) and source does it use? What is the stated clinical rationale that makes your prescription more than a copy? Is the company or its pharmacy currently subject to manufacturer litigation or board action — and what happens to your supply and your prepaid plan if a court order stops shipments mid-plan? What are the cancellation and refund terms? And how does the all-in price compare with the current manufacturer-direct cash price for the brand equivalent? Providers in our directory are annotated against this checklist as we verify them, and our rankings dock any provider that won't answer.

How enforcement actually lands, and what could reopen the lane

Understanding the machinery helps you read the news without whiplash. Enforcement against out-of-bounds compounding rarely begins with a raid; it begins with FDA warning letters and state-board actions, escalates through injunctions, and runs alongside the manufacturers' civil litigation against sellers of copies — a docket that grew steadily after the shortage designations ended. For the patient, the practical translation is that supply from borderline operators tends to vanish abruptly, mid-refill, with no transition plan; the operators bearing down on personalized, prescription-specific compounding under a physician's individualized rationale are the ones structured to survive scrutiny, which is exactly why our verification checklist asks who the pharmacy is before it asks what the price is. Could the mass-compounding era return? Two doors exist: a new official shortage — never impossible in a market this demand-shocked, and the reason we keep a watch item on our timeline — or litigation and rulemaking outcomes that redraw what "essentially a copy" means. Neither door is one to build a twelve-month health plan on. Plan on the law as it stands, keep a fallback from our coverage guide priced, and let reopenings be a pleasant surprise rather than a load-bearing assumption.

Running a state-board license check in five minutes

The single highest-value diligence act available to a consumer is also the least performed, so here is the walkthrough. Ask the telehealth service, in writing, for the name and state of the pharmacy that will dispense your medication — a legitimate operator answers in one message; evasion is itself the answer. Search the dispensing state's Board of Pharmacy license-verification portal (every state runs one; search "[state] board of pharmacy license verification") for the pharmacy's name: you're confirming an active license, checking for disciplinary actions, and noting whether it holds the non-resident licenses to ship into your state. Cross-check sterile-compounding credentials where listed, and for 503B outsourcing facilities, confirm the name against FDA's public registry. Ten minutes, zero cost, and it filters out the majority of the market's worst actors — because the one thing a gray operation cannot fake is a regulator's database saying it exists.

Questions people actually ask

If I already have a supply from the mass-compounding era, can I keep using it? Possession isn't the issue — provenance and freshness are. Product from a then-licensed pharmacy during the shortage window was lawfully dispensed to you; check beyond-use dates (compounded sterile products carry short ones), store per instructions, and plan your continuity through currently lawful channels rather than stockpiles.

Does "personalized dosing" on a telehealth site mean they've found the loophole? Sometimes it means genuine individualized prescribing with a clinical rationale, which remains legitimate compounding territory; sometimes it's a costume on a mass product. The tells are the ones this guide teaches: a real prescriber interaction, a named licensed pharmacy, a prescription tailored to you, and answers in writing when you ask how their model complies. Marketing language settles nothing; structure settles everything.

Who do I actually contact if I think an operator is out of bounds? The dispensing state's Board of Pharmacy takes complaints on pharmacies; FDA MedWatch takes adverse-event and product-quality reports; your own state's board handles the prescriber side. Reports are the raw material of the enforcement arc described above — the system sees what patients tell it.